Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Prevalence of rifampicin resistance by CB-NAAT in previously treated pulmonary tuberculosis cases

Mahendra Kumar Bainara, Ananda Datta, Dinesh Kumar Sharma
European Respiratory Journal 2016 48: PA2674; DOI: 10.1183/13993003.congress-2016.PA2674
Mahendra Kumar Bainara
1Respiratory Medicine, R.N.T Medical College, Udaipur, RajasthanIndia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ananda Datta
1Respiratory Medicine, R.N.T Medical College, Udaipur, RajasthanIndia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dinesh Kumar Sharma
1Respiratory Medicine, R.N.T Medical College, Udaipur, RajasthanIndia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

INTRODUCTION: CB-NAAT is an automated, semi-quantitative real time PCR assay designed for the rapid and simultaneous detection of mycobacterium tuberculosis and Rifampicin resistance within 2 hours. 'Rifampicin' resistance is a surrogate marker of MDR-TB.

AIMS & OBJECTIVE: To find out Rifampicin resistance in previously treated pulmonary TB patients by CB-NAAT.

METHOD: this was a prospective study conducted over 1 year in 100 previously treated pulmonary TB cases.Two sputum samples of all study subjects were sent for microscopy and CB-NAAT. All data was analysed by Social Sciences v 16.

RESULT: Out of 67 sputum positive cases, 66 (98.50%) were confirmed by CB-NAAT and in 1(1.50%) patients MTB was not detected. Among the MTB detected cases,79.10% were 'R' sensitive and 'R' resistance was 19.40%. among R resistant cases, 46.15%,23.07%,30.77% were failure cases, treatment after default cases and relapse cases respectively. Among 33 sputum negative cases, 48.48% showed MTB positive,out of which 42.42% was R sensitive and 6.06% was R resistant. Overall prevalence of 'R' resistance in previously treated pulmonary TB patients was 15% (15/100).

CONCLUSION: In this study we found 'R' resistance not only in sputum positive previously treated cases but also sputum negative cases which may be a hidden source of MDR-TB. So this test should be encouraged in sputum negative previously treated TB patients.

REFERANCES1. Tuberculosis. WHO Global Tuberculosis Report 2014. http://www.who.int/tb/publications/factsheet_global.pdf.2. Boehme CC, Nabeta P et al. Rapid molecular detection of tuberculosis and rifampicin resistance. N Eng J Med 2010; 363: 1005-1015.

  • Infections
  • Copyright ©the authors 2016
Previous
Back to top
Vol 48 Issue suppl 60 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prevalence of rifampicin resistance by CB-NAAT in previously treated pulmonary tuberculosis cases
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Prevalence of rifampicin resistance by CB-NAAT in previously treated pulmonary tuberculosis cases
Mahendra Kumar Bainara, Ananda Datta, Dinesh Kumar Sharma
European Respiratory Journal Sep 2016, 48 (suppl 60) PA2674; DOI: 10.1183/13993003.congress-2016.PA2674

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Prevalence of rifampicin resistance by CB-NAAT in previously treated pulmonary tuberculosis cases
Mahendra Kumar Bainara, Ananda Datta, Dinesh Kumar Sharma
European Respiratory Journal Sep 2016, 48 (suppl 60) PA2674; DOI: 10.1183/13993003.congress-2016.PA2674
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • A study of prevalence of depression in patients with multi drug resistant tuberculosis
  • Range of additional drug resistance of M.tuberculosis in XDR-TB patients
  • Vitamin D binding protein (DBP) levels during tuberculosis treatment are affected by DBP genotype / haplotype but not by total vitamin D levels
Show more 10.2 Tuberculosis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society